Negative allosteric modulation of the glucagon receptor by RAMP2

Receptor activity-modifying proteins (RAMPs) modulate the activity of many Family B heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs). The glucagon receptor (GCGR), a Family B GPCR responsible for maintenance of proper blood sugar levels, interacts with RAMP2, though the purpose and consequence of this interaction is poorly understood. Using a series of biochemical and cell-based assays, we show that RAMP2 interacts with and broadly inhibits GCGR-induced downstream signaling. Hydrogen-deuterium exchange monitored by mass spectrometry (HDX-MS) demonstrates that RAMP2 enhances local flexibility in select locations in and near the receptor extracellular domain (ECD) as well as at a key region in the 6th transmembrane helix, while single-molecule fluorescence resonance energy transfer (smFRET) experiments show that this RAMP2-induced ECD disorder results in inhibition of active and intermediate states of the intracellular face of the receptor. Using cryo-electron microscopy (cryoEM), we determined the structure of the GCGR-Gs complex at 2.9 Å resolution in the presence of RAMP2. RAMP2 apparently does not interact with GCGR in an ordered manner, yet the ECD of GCGR is indeed largely disordered in the presence of RAMP2. This disorder is accompanied by rearrangements of several key areas of the receptor, resulting in the formation of a likely unproductive complex. Together, our studies suggest that RAMP2 acts as a negative allosteric modulator of GCGR by enhancing conformational sampling of the ECD.

[1]  Hideaki E. Kato,et al.  Endogenous ligand recognition and structural transition of a human PTH receptor. , 2022, Molecular cell.

[2]  P. Sexton,et al.  A structural basis for amylin receptor phenotype , 2022, Science.

[3]  S. Marqusee,et al.  The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes , 2022, Nature Structural & Molecular Biology.

[4]  Hideaki E. Kato,et al.  Atypical structural snapshots of human cytomegalovirus GPCR interactions with host G proteins , 2022, Science advances.

[5]  Shaoyong Lu,et al.  Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor , 2022, Computational and structural biotechnology journal.

[6]  U. Zabel,et al.  Functional modulation of PTH1R activation and signalling by RAMP2 , 2021, bioRxiv.

[7]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[8]  M. J. Robertson,et al.  G-protein activation by a metabotropic glutamate receptor , 2021, Nature.

[9]  D. Carling,et al.  Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling , 2021, bioRxiv.

[10]  G. Ladds,et al.  RAMPs regulate signalling bias and internalisation of the GIPR , 2021, bioRxiv.

[11]  David J. Fleet,et al.  3D Variability Analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM. , 2021, Journal of structural biology.

[12]  J. Javitch,et al.  Agonist-induced formation of unproductive receptor-G12 complexes , 2020, Proceedings of the National Academy of Sciences.

[13]  J. M. Mathiesen,et al.  Structural insights into differences in G protein activation by family A and family B GPCRs , 2020, Science.

[14]  I. Bahar,et al.  Allosteric interactions in the parathyroid hormone GPCR–arrestin complex formation , 2020, Nature Chemical Biology.

[15]  M. J. Robertson,et al.  Structures of metabotropic GABAB receptor , 2020, Nature.

[16]  P. Sexton,et al.  Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. , 2020, ACS pharmacology & translational science.

[17]  P. Sexton,et al.  Structural basis of Gs and Gi recognition by the human glucagon receptor , 2020, Science.

[18]  P. Sexton,et al.  Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. , 2020, Molecular cell.

[19]  Hideaki E. Kato,et al.  Structure of the Neurotensin Receptor 1 in complex with β-arrestin 1 , 2020, Nature.

[20]  David J. Fleet,et al.  Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction , 2019, Nature Methods.

[21]  A. Pioszak,et al.  RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors. , 2020, Advances in pharmacology.

[22]  E. Isacoff,et al.  Conformational pathway provides unique sensitivity to a synaptic mGluR , 2019, Nature Communications.

[23]  Kelly K. Lee,et al.  Bridging protein structure, dynamics, and function using hydrogen/deuterium‐exchange mass spectrometry , 2019, Protein science : a publication of the Protein Society.

[24]  Robert M. Williams,et al.  Perturbation of the interactions of calmodulin with GRK5 using a natural product chemical probe , 2019, Proceedings of the National Academy of Sciences.

[25]  M. Uhlén,et al.  Multiplexed analysis of the secretin-like GPCR-RAMP interactome , 2019, Science Advances.

[26]  W. Baumeister,et al.  Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor , 2018, Nature.

[27]  Conrad C. Huang,et al.  UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.

[28]  Christopher J. Williams,et al.  MolProbity: More and better reference data for improved all‐atom structure validation , 2018, Protein science : a publication of the Protein Society.

[29]  T. Heise,et al.  Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog , 2017, Diabetes Care.

[30]  R. Stevens,et al.  Extending the Structural View of Class B GPCRs. , 2017, Trends in biochemical sciences.

[31]  S. Bloom,et al.  RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling , 2017, Endocrinology.

[32]  Jonathan A. Javitch,et al.  Single-molecule analysis of ligand efficacy in β2AR-G protein activation , 2017, Nature.

[33]  Arthur Christopoulos,et al.  Phase-plate cryo-EM structure of a class B GPCR-G protein complex , 2017, Nature.

[34]  M. Tschöp,et al.  The New Biology and Pharmacology of Glucagon. , 2017, Physiological reviews.

[35]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[36]  P. Sexton,et al.  Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. , 2017, Chemical reviews.

[37]  R. Riek,et al.  Micelles, Bicelles, and Nanodiscs: Comparing the Impact of Membrane Mimetics on Membrane Protein Backbone Dynamics , 2016, Angewandte Chemie.

[38]  B. Kobilka,et al.  Structure and dynamics of GPCR signaling complexes , 2017, Nature Structural & Molecular Biology.

[39]  L. Bankir,et al.  Glucagon actions on the kidney revisited: possible role in potassium homeostasis. , 2016, American journal of physiology. Renal physiology.

[40]  Mingyao Liu,et al.  Differential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled Receptors* , 2016, The Journal of Biological Chemistry.

[41]  Daniel S. Terry,et al.  Single-molecule imaging of non-equilibrium molecular ensembles on the millisecond timescale , 2016, Nature Methods.

[42]  G. Ladds,et al.  Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)* , 2015, The Journal of Biological Chemistry.

[43]  E. Isacoff,et al.  Conformational dynamics of a class C G protein-coupled receptor , 2015, Nature.

[44]  J. M. Mathiesen,et al.  A cAMP Biosensor-Based High-Throughput Screening Assay for Identification of Gs-Coupled GPCR Ligands and Phosphodiesterase Inhibitors , 2015, Journal of biomolecular screening.

[45]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[46]  Chris de Graaf,et al.  Structure of the human glucagon class B G-protein-coupled receptor , 2013, Nature.

[47]  H. Lindmark,et al.  Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function , 2013, British journal of pharmacology.

[48]  Luís M. S. Loura Simple Estimation of Förster Resonance Energy Transfer (FRET) Orientation Factor Distribution in Membranes , 2012, International journal of molecular sciences.

[49]  I. Hötzel,et al.  Molecular basis for negative regulation of the glucagon receptor , 2012, Proceedings of the National Academy of Sciences.

[50]  N. Lee,et al.  Dual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins. , 2011, Experimental cell research.

[51]  Nathaniel Echols,et al.  The Phenix software for automated determination of macromolecular structures. , 2011, Methods.

[52]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[53]  H. Xu,et al.  Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.

[54]  Gilad Haran,et al.  Noise reduction in single-molecule fluorescence trajectories of folding proteins , 2004 .

[55]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[56]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[57]  A. E. Hirsh,et al.  Coevolution of gene expression among interacting proteins , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[59]  P. Sexton,et al.  Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.

[60]  R. B. Merrifield,et al.  Identification of an essential serine residue in glucagon: implication for an active site triad. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. B. Merrifield,et al.  Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist , 1989, Peptides.